Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...
Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback